2,000 Shares in Tempus AI, Inc. (NASDAQ:TEM) Acquired by FNY Investment Advisers LLC

FNY Investment Advisers LLC bought a new stake in shares of Tempus AI, Inc. (NASDAQ:TEM) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 2,000 shares of the company’s stock, valued at approximately $67,000.

Other institutional investors also recently added to or reduced their stakes in the company. Kovitz Investment Group Partners LLC acquired a new position in shares of Tempus AI during the third quarter valued at $1,367,000. Sumitomo Mitsui Trust Group Inc. increased its stake in Tempus AI by 1,591.2% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock valued at $68,922,000 after buying an additional 1,145,698 shares during the period. Captrust Financial Advisors bought a new stake in shares of Tempus AI during the 3rd quarter worth about $2,726,000. Dakota Wealth Management acquired a new stake in shares of Tempus AI in the 3rd quarter worth approximately $1,185,000. Finally, Sigma Planning Corp bought a new position in shares of Tempus AI in the third quarter valued at approximately $1,323,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Stock Up 9.7 %

TEM stock opened at $34.92 on Thursday. Tempus AI, Inc. has a one year low of $22.89 and a one year high of $79.49. The firm has a 50-day moving average of $47.24 and a two-hundred day moving average of $47.17. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Insider Activity at Tempus AI

In other Tempus AI news, EVP Andrew Polovin sold 51,504 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $42.39, for a total transaction of $2,183,254.56. Following the sale, the executive vice president now directly owns 246,085 shares of the company’s stock, valued at $10,431,543.15. The trade was a 17.31 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Bradley A. Keywell sold 395,800 shares of the stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total value of $16,999,610.00. Following the completion of the sale, the insider now owns 16,164,449 shares of the company’s stock, valued at $694,263,084.55. The trade was a 2.39 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 865,041 shares of company stock worth $35,917,673.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Guggenheim started coverage on Tempus AI in a research report on Monday, December 9th. They issued a “buy” rating and a $74.00 target price for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $56.00 target price on shares of Tempus AI in a research note on Tuesday. Piper Sandler reiterated a “neutral” rating and issued a $70.00 price target (up from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Stifel Nicolaus lowered shares of Tempus AI from a “buy” rating to a “hold” rating and raised their price objective for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Finally, Wolfe Research assumed coverage on shares of Tempus AI in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $56.36.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.